Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 6, 2008

View Archived Issues

Recombinant BDNF fusion protein protects against Abeta-induced learning deficits

Positive preclinical results of new dengue virus vaccine candidates

Positive immunological data reported for ATX-MS-1467 in multiple sclerosis

PHOENIX 1 results show long-term efficacy of ustekinumab in psoriasis

Novel panErbB kinase inhibitor with potential against intracranial tumors profiled

Beta-blocker nadolol well tolerated and beneficial in asthma patients

Amgen and Takeda enter collaboration in Japan on up to 13 Amgen candidates

New treatments for arthritis and other inflammatory disorders disclosed in recent patent literature

Novel analgesic agents imparted in recent patents

New therapeutic agents for diabetes described in recent patents

Novel atypical antipsychotic drug profiled at Neurosearch

Biovitrum initiates process to move focus to specialist care diseases

SciClone initiates phase II trial of RP-101 in late-stage pancreatic cancer

Ziopharm initiates dosing in phase I/II studies of indibulin and palifosfamide

Solbec's Coramsine treatment discontinued in renal cell carcinoma patient

Biogen Idec submits IND application for BIIB-015

Advanced Cell Technology completes pre-IND meeting with FDA for RPE cell therapy

Alchemia reaches agreement with FDA to initiate clinical trial of HyCAMP

Progen executes definitive agreement to acquire CellGate

The FDA has accepted for review Centocor's BLA for ustekinumab for plaque psoriasis

Seaside awards USD 4.5 million collaborative research contract to Vanderbilt University

Zydus Cadila enters into collaborations with Prolong and Karo Bio

ActivBiotics receives orphan drug designation from the EMEA for M-40403

Alexza initiates AZ-007 phase I clinical trial

Dosing completed in first cohort in formal pharmacokinetic study for Zenvia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...